<--- Back to Details
First PageDocument Content
Myeloproliferative neoplasm / Patient advocacy / Essential thrombocytosis / Microsoft Push Notification Service / Caregiver / Polycythemia vera
Date: 2015-07-10 15:12:35
Myeloproliferative neoplasm
Patient advocacy
Essential thrombocytosis
Microsoft Push Notification Service
Caregiver
Polycythemia vera

NOMINATION FORM FOR MPN HEROES NOMINATION FORM FOR MPN HEROES

Add to Reading List

Source URL: curemagazine.s3.amazonaws.com

Download Document from Source Website

File Size: 158,14 KB

Share Document on Facebook

Similar Documents

Myeloproliferative neoplasm / Patient advocacy / Essential thrombocytosis / Microsoft Push Notification Service / Caregiver / Polycythemia vera

NOMINATION FORM FOR MPN HEROES NOMINATION FORM FOR MPN HEROES

DocID: 1oHQS - View Document

Medicine / Clinical medicine / Lymphatic system / Stem cells / Medical terminology / Myelofibrosis / Hematology / Transplantation medicine / Myeloproliferative neoplasm / Essential thrombocytosis / Thrombocytosis / Fibrosis

1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62

DocID: 1ohLr - View Document

Hematology / Clinical medicine / Medicine / Acute myeloid leukemia / Myeloproliferative neoplasm / Leukemia / Pathology / Myelodysplastic syndrome / Acute leukemia / Essential thrombocytosis / Hematologic disease

1 Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago

DocID: 1o8ES - View Document

Medicine / Chemistry / Clinical medicine / Lactams / Clinical pharmacology / Orphan drugs / Anagrelide / Adverse effect / Thrombocytosis / Ranitidine / Essential thrombocytosis / Hydroxycarbamide

Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No)

DocID: 1lIPi - View Document

Myelofibrosis / Essential thrombocytosis / Myeloproliferative disease / Plateletpheresis / Ruxolitinib / Megakaryocyte / Platelet / Bone marrow / Anemia / Medicine / Biology / Anatomy

Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard

DocID: 19YPO - View Document